Identifying early responses to kidney cancer treatment using exosomes
Exosome Signatures of Kidney Cancer Response to Immune Checkpoint Inhibitor
['FUNDING_R21'] · STANFORD UNIVERSITY · NIH-11114815
This study is looking at tiny particles called exosomes in blood and urine to see if they can help doctors tell how well patients with advanced kidney cancer are responding to a combination treatment, so patients can get the right care faster and avoid treatments that aren't working.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-11114815 on ClinicalTrials.gov |
What this research studies
This research investigates how exosomes, which are tiny particles released by cells, can serve as early indicators of how well patients with metastatic renal cell carcinoma are responding to a combination treatment of nivolumab and ipilimumab. By analyzing blood and urine samples, the study aims to detect specific proteins and RNA in exosomes that correlate with changes in tumor size, allowing for quicker assessment of treatment effectiveness. This could help patients avoid unnecessary side effects from ineffective therapies and transition to more effective treatments sooner.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic renal cell carcinoma who are starting treatment with nivolumab and ipilimumab.
Not a fit: Patients who are not undergoing treatment with nivolumab and ipilimumab or those with non-metastatic kidney cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enable earlier detection of treatment responses, improving patient outcomes and reducing unnecessary side effects.
How similar studies have performed: Previous research has shown promise in using exosomes as biomarkers for treatment response in various cancers, suggesting a potential for success in this novel application.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FAN, ALICE CHEN — STANFORD UNIVERSITY
- Study coordinator: FAN, ALICE CHEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.